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STo the Editor: Anderson-Fabry disease (AFD) is an X-linked
ysosomal storage disorder caused by mutations in the gene
ncoding alpha-galactosidase A. The resultant deficiency in alpha-
alactosidase A leads to progressive intracellular accumulation of
eutral glycosphingolipids throughout the body, causing multiorgan
ysfunction (1,2). The most common cardiac abnormality is progres-
ive left ventricular (LV) hypertrophy associated with dyspnea and
ngina (1,2). Left ventricular outflow tract obstruction (LVOTO) has
ot been thought to be an important mechanism of symptoms
ecause previous studies have reported a very low incidence of
VOTO under resting conditions in patients with AFD (1,2). We
eport a case series in which patients with AFD and drug-refractory
xertional symptoms underwent exercise echocardiography to deter-
ine the mechanism of their functional limitation.
The cohort consisted of 14 patients (6 male [43%]; mean age
4.3  10 years, range 38 to 74 years) with AFD who had
oderate to severe cardiac symptoms without resting LVOTO (30
m Hg) on routine echocardiography. Two-dimensional, M-mode,
nd Doppler echocardiography were performed in accordance with
he American Society of Echocardiography guidelines (3).
Left ventricular cavity dimensions were measured in end-
iastole (LVedd) and end-systole. Ejection fraction was calculated
sing the Teichholz method (3). Papillary muscles were classified
s hypertrophic if either the vertical or horizontal diameter of at
east 1 of the 2 papillary muscles was more than 1.1 cm in the
hort-axis views (4). Maximal LV wall thickness was defined as the
reatest thickness in any segment measured in end-diastole (3).
he LV mass was calculated and indexed for body surface area (3).
Relative wall thickness was calculated with an upper limit of
normal of 0.43 (3). Systolic anterior motion (SAM) was defined as
incomplete if there was any movement of the mitral valve leaflets
Clinical and Echocardiographic CharacteristicsTable 1 Clini l and Ec ocardiographic Characteristics
Patient #
Age at
Evaluation, yrs Sex Mutation ERT
LVEDD,
mm
LVED
(Norm
1 63 F c.1025delG yes 43
2 38 F P343L yes 53
3 43 M R301Q yes 49
4 49 F G208H yes 45
5 56 F N215S yes 40
6 50 M N215S yes 42
7 44 F R301G yes 39
8 74 M N215S yes 39
9 59 F R301X yes 48
10 61 F A377D yes 51
11 46 M 358del6 yes 48
12 53 M I317T yes 50
13 65 F R301G yes 44
14 59 M N215S yes 47ASH  asymmetrical septal hypertrophy; BSA  body surface area; ERT  enzyme replacement therapy
aximal left ventricular wall thickness.(MVLs) or chordae toward the ventricular septal endocardium
without septal contact and as complete when there was contact with
the ventricular septum during systole. Left ventricular outflow tract
gradients (LVOTGs) were measured using continuous-wave Doppler
in the apical 5-chamber view. Mitral regurgitation was graded as
absent, trivial, mild, moderate, or severe. Groups were compared with
t tests for independent samples and Fisher exact tests.
All cardiac medications were discontinued for a minimum of 5
half-lives before the exercise study. LVOTGs were measured in
the supine and upright position. Patients performed symptom-
limited upright exercise on a bicycle ergometer using a ramp
protocol with simultaneous echocardiography during exercise and
recovery. The highest gradient measured was taken as the peak
LVOTG. Latent obstruction was defined as a peak LVOTG 50
mm Hg during or after exercise. Patients unable to perform
exercise underwent measurement of the LVOTG following the
administration of sublingual glyceryl trinitrate.
All patients were symptomatic at the time of evaluation. The
clinical and echocardiographic characteristics of the cohort are
shown in Table 1. The mean ejection fraction was 63  8% with
a mean indexed LVedd of 24 2mm/m2. Twelve patients (86%) had
dilated left atrium (mean area 23  3 cm2, range 19 to 30 cm2).
hirteen (93%) had increased indexed LV mass (mean 135  42
/m2, range 88.9 to 226.2 g/m2). The relative wall thickness was
ncreased in 13 patients (93%) (mean 0.62  0.2, range 0.32 to 1.0).
Thirteen patients (93%) underwent exercise stress echocardiogra-
hy. One patient (7%) was unable to exercise, and the LVOTG was
ssessed following sublingual glyceryl trinitrate. Six patients developed
ynamic LVOTO 50 mm Hg during exercise (latent obstruction)
Fig. 1). In 5 patients, the mechanism of obstruction was complete
AM of the MVLs. In 1 patient, the LVOTG was the result of a
A, mm/m2
nge 24–32)
MLVWT,
mm
Papillary Muscle
Hypertrophy
LVH
Pattern
Peak Gradient,
mm Hg
3 14  ASH 15
9 9  Nil 6
1 15  Concentric 145
6 12  Concentric 14
0 15  ASH 152
9 22  Concentric 101
1 14  Concentric 56
9 20  Concentric 95
4 15  Concentric 20
9 19  Apical 34
6 14  Concentric 20
7 18  Concentric 23
6 16  Concentric 58
2 14  ASH 15D/BS
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2; LVEDD  left ventricular end-diastolic dimension; LVH  left ventricular hypertrophy; MLVWT 
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June 28, 2011:88–91narrow LV outflow tract, the presence of a tendon running between
the septum and the papillary muscles, and contact betweenMVLs and
septum. A significant change in the grade of mitral regurgitation was
found in 1 patient (from trivial to moderate/severe on exercise).
In the cohort of 14 patients, the 6 patients with latent LVOTO
had smaller LV cavities compared with those of the 8 patients
without latent LVOTO (mean LVedd/body surface area 21.5
mm/m2 and 26.2 mm/m2, respectively, p  0.007; mean relative
wall thickness 0.73 and 0.53, respectively, p  0.02). Patients with
latent LVOTO did not differ from patients without latent LVOTO
in terms of mean age (55.3 vs. 53.5 years, p 0.95), sex (50% vs. 38%
ale, p 0.99), mean ejection fraction (60.1% vs. 65.7%, p 0.44),
ean maximal LV wall thickness (17.0 vs. 14.4 mm, p 0.11), mean
ndexed LV mass (132.8 vs. 135.8 g/m2, p  0.90), papillary muscle
hypertrophy (83% vs. 75%, p  0.99), and incomplete SAM of the
MVLs at rest (67% vs. 13%, p  0.09).
Three of the 6 patients with exercise-induced LVOTO were
treated with calcium antagonists or beta-blockers; 2 patients
underwent dual-chamber pacemaker implantation for conduction
disease and refractory symptoms secondary to LVOTO. Two
patients (both women) went on to have surgical septal myectomy
(1 of these patients failed dual-chamber pacing) with subsequent
LVOTG reduction and clinical and functional improvement.
To the best of our knowledge, we documented for the first time
the presence of provocable LVOTO in symptomatic patients with
AFD with cardiac involvement and successful surgical septal
myectomy procedures in 2 women affected with the disease. The
reason for the low prevalence of LVOTO under resting conditions
in patients with AFD is uncertain, but it probably relates to
Figure 1 Rest and Stress LVOTG
LVOTG  left ventricular outflow tract gradient.differences in LV and mitral valve anatomy in comparison with phypertrophic cardiomyopathy. Patients with provocable LVOTO
in this study had smaller LV cavities compared with those without
latent LVOTO, and we therefore speculate that it is the reduction
in cavity size caused by exercise and papillary muscle hypertrophy
that predisposes some patients with AFD to LVOTO.
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